Please login to the form below

Not currently logged in
Email:
Password:

Collaboration on stroke therapy

NeuroVive Pharmaceutical and to-BBB are to work together to develop therapies for stroke and other acute neurodegenerative diseases

Swedish drug company, NeuroVive Pharmaceutical and Dutch biotech to-BBB are to work together to develop therapies for stroke and other acute neurodegenerative diseases.

NeuroVive Pharmaceutical is engaged in research and development of nerve cell-protecting and regenerative cyclosporin-based pharmaceuticals for the treatment of traumatic brain injuries (TBI) and other neurological diseases, while to-BBB works in the field of enhanced drug delivery across the blood-brain barrier.

"The collaboration with to-BBB opens up the possibility of treating brain disorders beyond TBI. There is a tremendous unmet medical need in treating patients with acute neurodegeneration such as stroke, cardiac-arrest-induced brain damage and spinal cord injuries, where one can expect the blood-brain barrier (BBB) to significantly prevent drug penetration to the central nervous system (CNS)," said Dr Eskil Elmer, CSO of NeuroVive.

Pieter Gaillard, CSO of to-BBB, added: "The BBB is indeed a significant obstacle in the treatment of CNS disorders. to-BBB's proprietary G-Technology can safely enhance drug delivery to the brain and we are excited to address this with NeuroVive's cyclosporin-based pharmaceuticals."

Mikael Brönnegård, CEO of NeuroVive, said: "Currently there are no approved pharmacological or cellular primary neuroprotective treatments for stroke and spinal cord injuries. Consequently, the need to develop treatment for acute degenerative disorders has never been greater than it is today. The deal with to-BBB has the potential to generate drugs for large markets in CNS diseases such as stroke."

NeuroVive will fund the initial development up to preclinical Proof of Concept, after which the two companies will develop and commercialise the product jointly. 

25th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics